AAPL283.78+8.63 (+3.14%) ▲|ABBV253.35+10.21 (+4.20%) ▲|ABT94.12+0.88 (+0.94%) ▲|ACN128.98+3.16 (+2.51%) ▲|ADBE202.73+9.32 (+4.82%) ▲|AMAT626.84-41.16 (-6.16%) ▼|AMD521.58-10.99 (-2.06%) ▼|AMGN358.33+5.51 (+1.56%) ▲|AMT175.59+6.87 (+4.07%) ▲|AMZN232.69+5.68 (+2.50%) ▲|AVGO365.02-13.89 (-3.67%) ▼|AXP340.36-2.10 (-0.61%) ▼|BA217.25-0.87 (-0.40%) ▼|BAC57.88-0.31 (-0.53%) ▼|BKNG181.46+4.41 (+2.49%) ▲|BLK964.71-7.21 (-0.74%) ▼|BMY57.52+2.13 (+3.85%) ▲|BNY143.56-1.87 (-1.29%) ▼|BRK-B498.66+10.85 (+2.22%) ▲|C141.76-3.22 (-2.22%) ▼|CAT997.47-59.54 (-5.63%) ▼|CL92.07+1.01 (+1.11%) ▲|CMCSA23.17+0.48 (+2.12%) ▲|COF204.00-0.90 (-0.44%) ▼|COP105.96-0.45 (-0.42%) ▼|COST952.54+10.30 (+1.09%) ▲|CRM158.37+8.18 (+5.45%) ▲|CSCO113.77-5.20 (-4.37%) ▼|CVS104.34-0.32 (-0.31%) ▼|CVX171.06-1.18 (-0.69%) ▼|DE613.24-17.52 (-2.78%) ▼|DHR196.19+3.38 (+1.75%) ▲|DIS98.79+0.74 (+0.75%) ▲|DUK128.40+1.29 (+1.01%) ▲|EMR143.49-1.85 (-1.27%) ▼|FDX318.53-10.91 (-3.31%) ▼|GD346.71+2.01 (+0.58%) ▲|GE369.00-2.36 (-0.64%) ▼|GEV1,045.17-40.30 (-3.71%) ▼|GILD127.88+4.04 (+3.26%) ▲|GM78.10-0.43 (-0.55%) ▼|GOOG334.69-7.50 (-2.19%) ▼|GOOGL337.39-6.32 (-1.84%) ▼|GS1,019.61-45.48 (-4.27%) ▼|HD348.86+3.86 (+1.12%) ▲|HON232.21+0.97 (+0.42%) ▲|IBM271.63+13.36 (+5.17%) ▲|INTC128.32-4.55 (-3.42%) ▼|INTU267.72+12.65 (+4.96%) ▲|ISRG404.70+5.01 (+1.25%) ▲|JNJ254.66+9.78 (+3.99%) ▲|JPM329.05-6.07 (-1.81%) ▼|KO82.63+2.21 (+2.75%) ▲|LIN519.62-2.66 (-0.51%) ▼|LLY1,208.12+80.43 (+7.13%) ▲|LMT507.40+2.38 (+0.47%) ▲|LOW222.48+0.55 (+0.25%) ▲|LRCX379.09-22.73 (-5.66%) ▼|MA499.02+10.10 (+2.07%) ▲|MCD269.76+5.22 (+1.97%) ▲|MDLZ60.79-0.41 (-0.67%) ▼|MDT80.98+1.18 (+1.48%) ▲|META550.25+7.38 (+1.36%) ▲|MMM164.01-3.96 (-2.36%) ▼|MO73.79+0.58 (+0.79%) ▲|MRK128.66+3.21 (+2.56%) ▲|MS212.03-9.01 (-4.08%) ▼|MSFT372.97+20.14 (+5.71%) ▲|MU1,132.33-81.23 (-6.69%) ▼|NEE88.56+0.86 (+0.98%) ▲|NFLX73.81+2.91 (+4.10%) ▲|NKE40.75-0.15 (-0.37%) ▼|NOW98.34+8.82 (+9.85%) ▲|NVDA192.53-3.21 (-1.64%) ▼|ORCL148.53-3.93 (-2.58%) ▼|PEP141.39+1.87 (+1.34%) ▲|PFE24.29+0.62 (+2.62%) ▲|PG149.02+0.52 (+0.35%) ▲|PLTR112.93+5.66 (+5.28%) ▲|PM180.77+1.84 (+1.03%) ▲|QCOM189.39-15.51 (-7.57%) ▼|RTX187.99+1.40 (+0.75%) ▲|SBUX104.60+1.44 (+1.40%) ▲|SCHW90.67+1.23 (+1.38%) ▲|SO97.16+1.25 (+1.30%) ▲|SPG226.89+1.40 (+0.62%) ▲|T22.72+0.30 (+1.34%) ▲|TMO513.03+7.28 (+1.44%) ▲|TMUS182.68+1.11 (+0.61%) ▲|TSLA379.71+4.59 (+1.22%) ▲|TXN285.43-26.39 (-8.46%) ▼|UBER76.20+3.95 (+5.47%) ▲|UNH427.89+12.36 (+2.97%) ▲|UNP268.35+0.62 (+0.23%) ▲|UPS108.14-1.17 (-1.07%) ▼|USB60.91-0.30 (-0.49%) ▼|V336.23+5.71 (+1.73%) ▲|VZ46.54+0.47 (+1.02%) ▲|WFC83.86-0.88 (-1.04%) ▼|WMT115.69-0.09 (-0.08%) ▼|XOM136.54-1.01 (-0.73%) ▼|AAPL283.78+8.63 (+3.14%) ▲|ABBV253.35+10.21 (+4.20%) ▲|ABT94.12+0.88 (+0.94%) ▲|ACN128.98+3.16 (+2.51%) ▲|ADBE202.73+9.32 (+4.82%) ▲|AMAT626.84-41.16 (-6.16%) ▼|AMD521.58-10.99 (-2.06%) ▼|AMGN358.33+5.51 (+1.56%) ▲|AMT175.59+6.87 (+4.07%) ▲|AMZN232.69+5.68 (+2.50%) ▲|AVGO365.02-13.89 (-3.67%) ▼|AXP340.36-2.10 (-0.61%) ▼|BA217.25-0.87 (-0.40%) ▼|BAC57.88-0.31 (-0.53%) ▼|BKNG181.46+4.41 (+2.49%) ▲|BLK964.71-7.21 (-0.74%) ▼|BMY57.52+2.13 (+3.85%) ▲|BNY143.56-1.87 (-1.29%) ▼|BRK-B498.66+10.85 (+2.22%) ▲|C141.76-3.22 (-2.22%) ▼|CAT997.47-59.54 (-5.63%) ▼|CL92.07+1.01 (+1.11%) ▲|CMCSA23.17+0.48 (+2.12%) ▲|COF204.00-0.90 (-0.44%) ▼|COP105.96-0.45 (-0.42%) ▼|COST952.54+10.30 (+1.09%) ▲|CRM158.37+8.18 (+5.45%) ▲|CSCO113.77-5.20 (-4.37%) ▼|CVS104.34-0.32 (-0.31%) ▼|CVX171.06-1.18 (-0.69%) ▼|DE613.24-17.52 (-2.78%) ▼|DHR196.19+3.38 (+1.75%) ▲|DIS98.79+0.74 (+0.75%) ▲|DUK128.40+1.29 (+1.01%) ▲|EMR143.49-1.85 (-1.27%) ▼|FDX318.53-10.91 (-3.31%) ▼|GD346.71+2.01 (+0.58%) ▲|GE369.00-2.36 (-0.64%) ▼|GEV1,045.17-40.30 (-3.71%) ▼|GILD127.88+4.04 (+3.26%) ▲|GM78.10-0.43 (-0.55%) ▼|GOOG334.69-7.50 (-2.19%) ▼|GOOGL337.39-6.32 (-1.84%) ▼|GS1,019.61-45.48 (-4.27%) ▼|HD348.86+3.86 (+1.12%) ▲|HON232.21+0.97 (+0.42%) ▲|IBM271.63+13.36 (+5.17%) ▲|INTC128.32-4.55 (-3.42%) ▼|INTU267.72+12.65 (+4.96%) ▲|ISRG404.70+5.01 (+1.25%) ▲|JNJ254.66+9.78 (+3.99%) ▲|JPM329.05-6.07 (-1.81%) ▼|KO82.63+2.21 (+2.75%) ▲|LIN519.62-2.66 (-0.51%) ▼|LLY1,208.12+80.43 (+7.13%) ▲|LMT507.40+2.38 (+0.47%) ▲|LOW222.48+0.55 (+0.25%) ▲|LRCX379.09-22.73 (-5.66%) ▼|MA499.02+10.10 (+2.07%) ▲|MCD269.76+5.22 (+1.97%) ▲|MDLZ60.79-0.41 (-0.67%) ▼|MDT80.98+1.18 (+1.48%) ▲|META550.25+7.38 (+1.36%) ▲|MMM164.01-3.96 (-2.36%) ▼|MO73.79+0.58 (+0.79%) ▲|MRK128.66+3.21 (+2.56%) ▲|MS212.03-9.01 (-4.08%) ▼|MSFT372.97+20.14 (+5.71%) ▲|MU1,132.33-81.23 (-6.69%) ▼|NEE88.56+0.86 (+0.98%) ▲|NFLX73.81+2.91 (+4.10%) ▲|NKE40.75-0.15 (-0.37%) ▼|NOW98.34+8.82 (+9.85%) ▲|NVDA192.53-3.21 (-1.64%) ▼|ORCL148.53-3.93 (-2.58%) ▼|PEP141.39+1.87 (+1.34%) ▲|PFE24.29+0.62 (+2.62%) ▲|PG149.02+0.52 (+0.35%) ▲|PLTR112.93+5.66 (+5.28%) ▲|PM180.77+1.84 (+1.03%) ▲|QCOM189.39-15.51 (-7.57%) ▼|RTX187.99+1.40 (+0.75%) ▲|SBUX104.60+1.44 (+1.40%) ▲|SCHW90.67+1.23 (+1.38%) ▲|SO97.16+1.25 (+1.30%) ▲|SPG226.89+1.40 (+0.62%) ▲|T22.72+0.30 (+1.34%) ▲|TMO513.03+7.28 (+1.44%) ▲|TMUS182.68+1.11 (+0.61%) ▲|TSLA379.71+4.59 (+1.22%) ▲|TXN285.43-26.39 (-8.46%) ▼|UBER76.20+3.95 (+5.47%) ▲|UNH427.89+12.36 (+2.97%) ▲|UNP268.35+0.62 (+0.23%) ▲|UPS108.14-1.17 (-1.07%) ▼|USB60.91-0.30 (-0.49%) ▼|V336.23+5.71 (+1.73%) ▲|VZ46.54+0.47 (+1.02%) ▲|WFC83.86-0.88 (-1.04%) ▼|WMT115.69-0.09 (-0.08%) ▼|XOM136.54-1.01 (-0.73%) ▼|
21.2 C
New York
Sunday, June 28, 2026

Tag: novel

newssourceFORcompanyinformationcontent1releasesmarket

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’),  a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company.

Belay Diagnostics Announces the Validation of Vantage™ Assay for Evaluation of MGMT Promoter Methylation in Cerebrospinal Fluid

Validation Data on 60 Patients published in Cancer Genetics CHICAGO, July 7, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the development...

mRNA Sequencing Market Size to Hit USD 4.02 billion by 2031, Growing at 13.6% CAGR, Benefits from Surging Prevalence of Cancer | The Insight...

NEW YORK, July 7, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global mRNA sequencing market is observing...

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients...

-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population --

-- Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo --

Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe

Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe

Nuevocor Strengthens Board with Appointment of Thierry Abribat

SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the appointment of Dr....

Abinopharm, Inc. and EGT Synbio Announce Successful Human Clinical Trials on Oral L-Ergothioneine (Dr.Ergo®) for Skin Health

Human Clinical Trial of L-Ergothioneine (Dr.Ergo®) on Skin Health

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe...

Webcast to be held Monday, July 7th at 8:00 a.m. ET 
Webcast to be held Monday, July 7th at 8:00 a.m. ET

AI Buddy: Friend or Fad?

What can a purple alien teach us about human relationships? Turns out, more than your average AI chatbot. The alien in question is a...

Members Capital Management Completes Initial Deployment of Tokenised Reinsurance Fund

First of its kind institutional-grade fund opens access to a new and growing class of traditional and digital asset-native allocators HAMILTON, Bermuda, July 4, 2025...

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT

NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline.

HotSpot Therapeutics Presents Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025

BOSTON, July 4, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart...

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNovel

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers